A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are ...

On the heels of disappointing low-dose data results, Zealand Pharma is back with separate findings for its GLP-1/GLP-2 ...

[11] The absence of severe hypoglycemia is consistent with the glucose-dependent insulinotropic mechanism of GLP-1 receptor agonists. The rates of confirmed hypoglycemia were similar between the ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Recently, GLP-1 receptor agonist medications have been prescribed more commonly, in part due to their ability to ...

GLP-1 receptor agonist use was associated with a reduced risk of progressing to cirrhosis and related complications in ...

A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are ...

New research shows that metabolic bariatric surgery offers substantial protective benefits for patients with chronic kidney ...

In the last couple of days at the European Association for the Study of Diabetes (EASD) 60th Annual Meeting 2024, the potential of glucagon-like peptide-1 receptor (GLP-1R) agonists in type 1 ...

Viking Therapeutics' VK2735, a dual GLP-1/GIP receptor agonist, shows promising results ... weight loss treatments based on similar mechanisms of action. In addition, to those I have mentioned ...

This cohort study, including mostly patients with type 2 diabetes, does not show an association between use of glucagon-like peptide-1 (GLP-1) receptor agonists and an increased risk of suicide death, ...